is an important cause of bleeding in patients with cirrhosis associated with portal hypertension. Histologically, the condition is characterized by dilation of the mucosal and submucosal vessels ...

Treatment for portal hypertension in patients with cirrhosis is based on the use of β-blockers with or without organic nitrates; however, these agents are effective in less than 50% of patients ...

The mechanism by which patients with portal hypertension develop portal hypertensive ... of the free or wedged hepatic vein in hepatic cirrhosis. [22] Various studies have shown that the ...

The three abstracts are available for viewing by attendees on the AASLD website and will also be featured in the October supplement to the AASLD journal, Hepatology.

15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b ...